One stock that's been on my watch list for a while is CRISPR Therapeutics (NASDAQ: CRSP). The company has an intriguing ...

Newly patented CRISPR nuclease exhibits high activity in various prokaryotic and eukaryotic organisms Patent now opens up ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Intelligenome, a global leader in CRISPR-based in vitro diagnostic (IVD) technology, is pleased to announce that it has entered into a research and development subaward agreement with Cornell ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...

A new biosensor developed at the Department of Energy's Oak Ridge National Laboratory detects the emerging presence of fungus ...

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial momentum for its gene therapy CASGEVY, with patient initiations nearly tripling year over year. The company is preparing a regulatory ...

Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $46.93, demonstrating a -1.59% change from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day.

UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for ...